Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Potassium chloride acts as a source of potassium ions, essential for maintenance of cellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Dextrose provides caloric support and is metabolized to carbon dioxide and water, yielding energy. Sodium chloride maintains osmotic balance and fluid distribution.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
Intravenous infusion. Dose depends on electrolyte requirements, typically for maintenance or replacement. Potassium: 10-20 mEq/hour, not exceeding 20 mEq/hour or 200 mEq/day. Dextrose 10%: 100-200 mL/hour, not to exceed glucose infusion rate of 5 mg/kg/min. Sodium chloride 0.45%: as needed based on sodium deficit and fluid balance. Administer via central or peripheral line.
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateNone Documented
None Documented
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Potassium: Not applicable as the drug contains potassium, which distributes and is regulated; no terminal elimination half-life. Dextrose: variable, but glucose half-life ~2-4 hours depending on insulin. Sodium and chloride: long half-life, regulated by kidneys. Clinical context: drug used for repletion, not a typical pharmacokinetic agent.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Potassium: primarily renal (>90%) as K+; chloride: renal, following Na+ and Cl- reabsorption. Dextrose: metabolized. Sodium and chloride: renal handling matches intake. No biliary/fecal elimination for these ions.
Category C
Category A/B
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."